Abstract
The association between dermatomyositis (DM) and various types of malignancies has been reported in several studies, with an estimated frequency of about 20–25%. Cancer may appear before the onset of DM, concurrently with DM or after its onset. In the present report, the occurrence of typical DM in concomitance with development of skin metastases from previously treated breast cancer is described, suggesting the role of DM as paraneoplastic marker not only in association with the primary tumor but also in case of cutaneous involvement by cancer.
References
Parodi A, Caproni M, Marzano AV, De Simone C, La Placa M, Quaglino P, Veller Fornasa C, Zane C, Vaccaro M, Papini M, Fabbri P, Rebora A (2002) Dermatomyositis in 132 patients with different clinical subtypes: cutaneous signs, constitutional symptoms and circulating antibodies. Acta Derm Venereol 82:48–51. doi:10.1080/000155502753600894
Callen JP, Wortmann RL (2006) Dermatomyositis. Clin Dermatol 24:363–373. doi:10.1016/j.clindermatol.2006.07.001
Callen JP (2001) Relation between dermatomyositis and polymyositis and cancer. Lancet 357:85–86. doi:10.1016/S0140-6736(00)03535-2
Ponyi A, Constantin T, Garami M, András C, Tállai B, Váncsa A, Gergely L, Dankó K (2005) Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 1051:64–71. doi:10.1196/annals.1361.047
Levine SM (2006) Cancer and myositis: new insights into an old association. Curr Opin Rheumatol 18:620–624. doi:10.1097/01.bor.0000245721.02512.77
András C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P, Dankó K (2008) Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35:438–444
Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357:96–100. doi:10.1016/S0140-6736(00)03540-6
Borgia F, Vaccaro M, Guarneri F, Cannavó SP, Guarneri B (2001) Dermatomyositis associated with IgG myeloma. Br J Dermatol 144:200–201. doi:10.1046/j.1365-2133.2001.03984.x
Werth VP, Callen JP, Ang G, Sullivan KE (2002) Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol 119:617–620. doi:10.1046/j.1523-1747.2002.01869.x
Efthimiou P (2006) Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications. Semin Arthritis Rheum 36:168–172. doi:10.1016/j.semarthrit.2006.07.003
Chung L, Genovese MC, Fiorentino DF (2007) A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143:763–767. doi:10.1001/archderm.143.6.763
Carruba G, D’Agostino P, Miele M, Calabrò M, Barbera C, Bella GD, Milano S, Ferlazzo V, Caruso R, Rosa ML, Cocciadiferro L, Campisi I, Castagnetta L, Cillari E (2003) Estrogen regulates cytokine production and apoptosis in PMA-differentiated, macrophage-like U937 cells. J Cell Biochem 90:187–196. doi:10.1002/jcb.10607
Sereda D, Werth VP (2006) Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch Dermatol 142:70–72. doi:10.1001/archderm.142.1.70
Conflict of interest statement
None of the authors have any financial or any other kind of personal conflicts.
Author information
Authors and Affiliations
Corresponding author
Additional information
All authors have contributed significantly, and all authors are in agreement with the content of the manuscript.
Rights and permissions
About this article
Cite this article
Vaccaro, M., Borgia, F., Barbuzza, O. et al. Dermatomyositis and cutaneous metastases from breast cancer: simultaneous development and parallel course. Rheumatol Int 30, 1091–1093 (2010). https://doi.org/10.1007/s00296-009-1026-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-1026-0